Arcutis Biotherapeutics, Inc. (ARQT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Westlake Village, CA, 미국. 현재 CEO는 Todd Franklin Watanabe.
ARQT 을(를) 보유 IPO 날짜 2020-01-31, 342 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.11B.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of innovative treatments for dermatological diseases. The company's lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. Arcutis is advancing a robust pipeline that includes ARQ-154 for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a deeper-penetrating topical formulation designed to treat alopecia areata. The company was incorporated in 2016 and rebranded as Arcutis Biotherapeutics in 2019.
